TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06624644: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma

Sponsor: Linnaeus Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 135 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$17,698,296

Rescue Site Savings

+$11,667,348

Unlock Full NCT06624644 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06624644 Rescue Dossier →